Cosmo Pharmaceuticals NV (XTER:C43)
€ 69 -0.5 (-0.72%) Market Cap: 1.10 Bil Enterprise Value: 966.46 Mil PE Ratio: 15.53 PB Ratio: 2.16 GF Score: 82/100

Half Year 2019 Cosmo Pharmaceuticals NV Earnings Call Transcript

Jul 30, 2019 / 08:30AM GMT
Release Date Price: €14.5
Operator

Ladies and gentlemen, welcome to the Cosmo Pharmaceuticals Half Year Results Presentation Conference Call. I am Sherry, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to the management team of Cosmo Pharmaceuticals. Please go ahead.

Alessandro E. Della ChÃ
Cosmo Pharmaceuticals N.V. - CEO & Executive Director

Good morning, everyone. This is Alessandro Della Chà . Thanks for joining this call. Let me quickly walk you through the presentation. Let me tell you that this has been a very rich first half. We have been doing a lot of things. And the first slide and the second slide on the key events, I think, give a very fair representation of the work that has been done in the aftermath of the delay of Methylene Blue MMX. So one of the first things that we have done is that we have announced our revolutionary artificial intelligent product for the detection of lesion during colonoscopy.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot